Tag: Spyral
Attention turns to multi-organ denervation as new evidence supports “durability” of blood pressure reductions
New research will investigate the safety and efficacy of multi-organ, hepatic artery and renal a...
AHA 2022: SPYRAL HTN-ON MED study demonstrates “meaningful clinical benefits” consistent with other renal denervation trials
Medtronic has announced the six-month results from the full cohort of the SPYRAL HTN-ON MED clin...
EuroPCR 2022: Sham controlled trials have “revitalised” interest in renal denervation
“Renal denervation has travelled a very storied path over the last 10–15 years,” David Kandzari...
US FDA approve new study of Medtronic’s Spyral renal denervation system
The FDA have given Medtronic approval to begin a clinical trial to evaluate the Symplicity Spyra...
EuroPCR 2018: Positive data for renal denervation reignites interest in field
After two studies indicated that renal denervation lowers blood pressure both with and without a...
New trial of Symplicity Spyral approved
Medtronic has announced US FDA approval to begin an investigational device exemption (IDE) pivot...
